Q4 sales of Plavix and Aprovel family products are expected to decrease significantly due to net price adjustments of inventory in the channel.
The Company estimates that the favourable currency impact will be between approx. +1.5% and +2.5% on Q4 net sales and approx. +3% and +4% on Q4 business EPS.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.